Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-24, Stock:NVS, The news for the past five days is as follows:
2018-08-17: NEWS1: Merck, Eisai Get FDA Approval for Lenvima Label Expansion.NEWS2: Merck, Eisai Get FDA Approval for Lenvima Label Expansion.NEWS3: Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead.NEWS4: Array BioPharma Missed Sales Estimates for Q4 2018.NEWS5: Mylan’s Q2 Profit Fell against Backdrop of US Market Dynamics.NEWS6: The Swiss Stock Market Clung To A Small Gain.NEWS7: The Swiss Stock Market Clung To A Small Gain.NEWS8: ARAY Reports Record Revenue, PTIE Bleeds, EVOK To Face FDA In April.NEWS9: ARAY Reports Record Revenue, PTIE Bleeds, EVOK To Face FDA In April.
2018-08-20: NEWS1: LCI Whacked On Contract Loss, CWBR Awaits Data, Busy Months Ahead For PLSE.NEWS2: LCI Whacked On Contract Loss, CWBR Awaits Data, Busy Months Ahead For PLSE.NEWS3: Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose.NEWS4: Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose.NEWS5: Amgen Stock Up This Year So Far: Will the Rally Continue?.NEWS6: Amgen Stock Up This Year So Far: Will the Rally Continue?.NEWS7: Regeneron&apos;s Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose.NEWS8: Novan Rallies On Positive Early Results For Inflammatory Skin Disease Medication.NEWS9: Mylan Cuts Its Fiscal 2018 Guidance, Citing US Market Challenges.NEWS10: Mylan Has a Strong Balance Sheet despite Weak Q2 Performance.NEWS11: The Swiss Stock Market Rose On Hopes For Trade Agreement.NEWS12: The Swiss Stock Market Rose On Hopes For Trade Agreement.NEWS13: Novan Announces Promising Clinical Results with SB414.
2018-08-21: NEWS1: GSK Reportedly Seeks Initial Bids For $4 Bln Indian Horlicks Unit.NEWS2: GSK Reportedly Seeks Initial Bids For $4 Bln Indian Horlicks Unit.NEWS3: Glaxo Stock Up This Year So Far: Will the Rally Continue?.NEWS4: Glaxo Stock Up This Year So Far: Will the Rally Continue?.NEWS5: Glaxo Stock Up This Year So Far: Will the Rally Continue?.NEWS6: The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows.NEWS7: The Swiss Stock Market Recovered From Early Weakness.NEWS8: The Swiss Stock Market Recovered From Early Weakness.NEWS9: Mylan Finds a Disconnect between Market View and Intrinsic Value.
2018-08-22: NEWS1: Incyte’s Revenue Stream in Q2 2018.NEWS2: Insight: Toxin at heart of drug recall shows holes in medical safety net.NEWS3: Toxin at heart of drug recall shows holes in medical safety net.NEWS4: The Swiss Stock Market Pulled Back In Cautious Trade.NEWS5: The Swiss Stock Market Pulled Back In Cautious Trade.
2018-08-23: NEWS1: Novartis Breast Cancer Drug Meets Primary Goal in Phase III.NEWS2: Novartis Breast Cancer Drug Meets Primary Goal in Phase III.NEWS3: Update on Roche’s Oncology Drugs: Tarceva, Cotellic, and Erivedge.NEWS4: Roche: Recent Developments and Analysts’ Ratings in August.NEWS5: Novartis Breast Cancer Drug Meets Primary Goal in Phase III.NEWS6: CYRX: Commercial Support and Clinical Trial Revenue Ramping. Commercial Support Pipeline Increasing Long-Term Value.NEWS7: Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio.NEWS8: Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio.NEWS9: The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero.NEWS10: The Swiss Stock Market Held Onto A Small Gain.NEWS11: The Swiss Stock Market Held Onto A Small Gain.NEWS12: European Markets Finished Mostly Lower In Choppy Trade.NEWS13: European Markets Finished Mostly Lower In Choppy Trade.NEWS14: Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio.NEWS15: How Incyte’s Product Portfolio Is Looking in August.NEWS16: Novartis Breast Cancer Drug Trial a Success.NEWS17: Novartis: Phase III SOLAR-1 Trial On PI3K Inhibitor BYL719 Met Primary Goal.NEWS18: Novartis: Phase III SOLAR-1 Trial On PI3K Inhibitor BYL719 Met Primary Goal.

Answer: Rise